Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replimune Group Inc
(NQ:
REPL
)
11.90
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Replimune Group Inc
< Previous
1
2
Next >
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
August 08, 2024
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025.
Via
InvestorPlace
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 07, 2024
Via
Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
June 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
June 06, 2024
Via
Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
June 06, 2024
Via
Benzinga
Exposures
Fossil Fuels
Replimune Group: Q3 Earnings Insights
February 08, 2024
Via
Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
December 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Replimune Group
August 01, 2023
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
June 06, 2024
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was...
Via
Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
June 06, 2024
Via
Benzinga
Analyst Ratings for Replimune Group
June 07, 2023
Via
Benzinga
Recap: Replimune Group Q4 Earnings
May 18, 2023
Via
Benzinga
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024
May 16, 2024
REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024.
Via
InvestorPlace
Crude Oil Moves Lower; AutoZone Profit Tops Views
December 05, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 05, 2023
Via
Benzinga
Dow Falls 100 Points; ISM Services PMI Increases In November
December 05, 2023
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Replimune (REPL) Stock Down 48% Today?
December 05, 2023
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.
Via
InvestorPlace
US Stocks Down; JM Smucker Posts Upbeat Earnings
December 05, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Cancer-Focused Replimune Stock Today?
December 05, 2023
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 05, 2023
Via
Benzinga
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
June 09, 2023
The Nasdaq held near 52-week highs while small caps ramped up.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
June 05, 2023
Via
Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 05, 2023
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
Via
Benzinga
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
June 05, 2023
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference.
Via
Investor's Business Daily
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
April 13, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
December 12, 2022
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.